A new immunotherapy approach has shown promise as an effective treatment for antibiotic-resistant bacteria in a first-in-human trial involving a patient with chronic infection caused by Mycoplasma hominis. The trial was conducted at Brigham and Women’s Hospital.
The patient had been diagnosed with M. hominis septic polyarthritis in 2009 and had had several courses of antibiotic treatment but with no improvement. To create this targeted immunotherapy, SAB Biotherapeutics, a clinical-stage biopharmaceutical development company, vaccinated a transchromosomal (Tc) bovine with inactivated isolates of the patient’s bacteria. Antibodies were then harvested in the plasma and purified, after which the patient received infusions to combat the infection.
Treatment with the high-dose therapy resulted in reduced M. hominis burden and improved clinical parameters; the infusions were well-tolerated with no significant adverse events.
“This study provides the first clinical evidence showing the human polyclonal antibody therapeutic–produced from our natural DiversitAb immunotherapy platform–is safe, and provides an option for recalcitrant infection resistant bacteria where antibiotics and multiple other therapies were ineffective,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO, “This is an important step in furthering the development of this platform technology in infectious disease, including anti-microbial resistance.”
For more information visit SabBiotherapeutics.com.